Peptide education
CagriSema
Cagrilintide + Semaglutide · Cagri-Sema
CagriSema is Novo Nordisk's investigational once-weekly combination of two drugs: cagrilintide, a long-acting amylin analogue, and semaglutide, the GLP-1 agonist behind Ozempic and Wegovy. The pitch is two satiety pathways at once, and the phase 3 obesity trial reported 20.4% mean weight loss at 68 weeks, 22.7% under ideal-adherence analysis. It remains unapproved, though Novo filed a U.S. application in December 2025 with an FDA decision expected in late 2026. The head-to-head meant to crown it, REDEFINE 4 against tirzepatide, missed its primary endpoint.
CagriSema's phase 3 weight-loss data are among the strongest reported for an investigational metabolic drug, but its head-to-head against tirzepatide missed noninferiority and it is still not approved. Vials sold as CagriSema are two-molecule blends that no trial has validated.
Overview
Quick answer
CagriSema is a combination program, not a single peptide. Trial evidence for Novo's cagrilintide-plus-semaglutide program belongs to the studied fixed-ratio product. Online vials, research blends, clinic mixtures, and compounded products need separate identity, ratio, sterility, concentration, stability, and clinical-comparability support.
What is it?
A fixed combination of cagrilintide, an amylin analogue, and semaglutide, a GLP-1 agonist, studied as a once-weekly injection for obesity and type 2 diabetes. The logic is two complementary satiety pathways in one product.
Why do people talk about it?
The numbers: 20.4% mean weight loss in REDEFINE 1 and 22.7% under ideal-adherence analysis, plus diabetes trials reporting HbA1c and weight advantages over semaglutide. It anchors the whole what-comes-after-GLP-1 conversation.
What study schedules and listing claims are documented?
Trials used once-weekly subcutaneous treatment, commonly targeting 2.4 mg/2.4 mg, across 32 to 84 week programs depending on the study. Gray-market listings borrow that shorthand while their component ratios, sterility, and equivalence to Novo's material stay unverified.
Is it approved?
No. Novo announced a U.S. NDA filing for weight management in December 2025 and later pointed to an FDA decision expected in late 2026. A filing under review is not an approval label.
What causes confusion?
Three different things get collapsed into one name: approved semaglutide products, Novo's investigational fixed-ratio CagriSema trials, and online cagrilintide-plus-semaglutide blends assembled by sellers.
Reported practice
Commonly reported protocol
Combination-imitation discussion. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
REDEFINE 1 reported large mean weight-loss effects in adults with overweight or obesity without diabetes, and REDEFINE 2 reported a smaller but still meaningful effect in adults with type 2 diabetes.
A phase 2 diabetes trial, the PubMed-indexed REIMAGINE 2 phase 3 diabetes-comparator study, and Novo program updates support the combination's glycemic and weight effects in studied type 2 diabetes populations.
Trial records and company updates support investigational status, not a current FDA or EU approval claim for CagriSema. Novo announced a December 2025 U.S. NDA filing for weight management and later described an expected late-2026 FDA decision window.
FDA says cagrilintide cannot be used in compounding under federal law, and FDA warnings around compounded semaglutide and online GLP-1-family products make product-quality claims a central issue.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| CagriSema produces major weight loss. | Supported in the studied populations. REDEFINE 1 reported mean weight loss of 20.4% under the treatment-policy analysis and 22.7% under the ideal-adherence analysis at 68 weeks. REDEFINE 2 reported 13.7% and 15.7% respectively in adults with obesity or overweight plus type 2 diabetes. | The combination joins amylin-pathway signaling from cagrilintide with GLP-1 receptor agonism from semaglutide, which fits the appetite and metabolic-control rationale. | Online discussion and vendor pages commonly present the name as a next weight-loss step after semaglutide or tirzepatide. Those discussions say little about whether non-trial products match the studied material. | Strong as a clinical-trial weight-loss signal. It does not tell you what is inside a clinic blend or research-use vial. |
| CagriSema improves blood sugar in type 2 diabetes. | Supported in diabetes studies. The phase 2 trial reported larger HbA1c and weight reductions with cagrilintide plus semaglutide than with cagrilintide alone. REIMAGINE 2 is now PubMed-indexed, and Novo's program updates reported superior HbA1c reduction and weight loss versus semaglutide across tested doses. | Semaglutide's GLP-1 activity fits a glucose-control role, while cagrilintide adds an amylin-related satiety and metabolic signal. | Forum and clinic-style discussion often focuses more on body weight than diabetes endpoints, so the diabetes claim needs named trials. | Supported for studied type 2 diabetes populations; final regulator-reviewed prescribing details are not available yet. |
| CagriSema is better than tirzepatide. | Novo has reported that the REDEFINE 4 head-to-head trial did not meet the primary noninferiority endpoint versus tirzepatide 15 mg after 84 weeks in 809 adults; that is direct head-to-head context, not a clean superiority claim. | Adding an amylin analogue is scientifically important, but superiority depends on direct trial context, comparator dose, population, and adherence. | Online comparisons are common because the headline weight-loss numbers are large. | Comparisons with tirzepatide need direct head-to-head evidence and exact trial context. Indirect numbers skip differences in trial design, population, adherence, and comparator dose. |
| Gray-market CagriSema is the same as the trial drug. | No human trial verifies that online research blends match the clinical product, component ratio, release testing, storage, or patient exposure used in Novo's studies. | This is a product-identity and injectable-quality question, not a receptor-pharmacology question. | Cited vendor listings describe research-use blends with COA, HPLC, and MS claims. That paperwork may describe a seller's testing package, but it does not establish sterility, endotoxin control, correct fill concentration, lawful status, or clinical equivalence. | Trial evidence covers outcomes in studied settings. Seller paperwork still has to show identity, ratio, sterility, concentration, chain of custody, and legal status. |
| CagriSema has settled cardiovascular-outcome benefit. | No completed CagriSema cardiovascular-outcomes result is available in the cited materials. Weight, HbA1c, and cardiometabolic markers do not substitute for a completed cardiovascular outcomes result for the combination. | Metabolic improvements can make cardiovascular research plausible, but outcomes trials answer whether event risk changes. | Marketing and forum discussion may infer heart benefit from weight loss or semaglutide familiarity. | Cardiovascular outcomes remain an open question until CagriSema-specific outcomes data report. |
Bottom line
Main takeaway
CagriSema is a promising investigational combination, not an approved product and not a generic label for any cagrilintide-plus-semaglutide vial. The trial results describe Novo's fixed-ratio drug alone.
The data are substantial, and the details decide their meaning: who was studied, which analysis produced the headline number, and whether the source is a trial, a Novo update, FDA material, or a vendor page. REDEFINE 4 is the standing reminder that bigger numbers did not beat tirzepatide head-to-head.
REDEFINE 1 and 2, the phase 2 diabetes trial, REIMAGINE 2, and FDA compounding materials carry the evidence. Vendor COAs document what sellers advertise, not equivalence to the studied product.
Identity
What it is
CagriSema pairs two long-acting molecules with different satiety mechanisms: cagrilintide works through amylin receptors, semaglutide through GLP-1 receptors. The hypothesis is additive weight loss from parallel pathways, tested mostly at a fixed 2.4 mg/2.4 mg ratio in the longer trials.
The attention is earned by results: phase 3 obesity trials reporting 13.7% to 22.7% mean weight loss depending on population and analysis, and a diabetes program reporting HbA1c and weight advantages over semaglutide.
The counterweight is REDEFINE 4, a company-reported head-to-head where CagriSema produced 23% mean weight loss but did not meet noninferiority against tirzepatide 15 mg. That does not make the drug weak; it makes the clearly-better-than-everything framing unsupported.
Meanwhile the name circulates in gray-market blends of separately sourced cagrilintide and semaglutide. Those products imitate the concept without the fixed ratio, release testing, or clinical validation behind the trial material.
How people talk about it online
CagriSema is usually framed as the next step after GLP-1 drugs: bigger weight-loss numbers, a second pathway, maybe an answer to plateaus. Whether adding cagrilintide changes the GI tolerability picture runs through the same threads.
Gray-market listings present CagriSema as research-use lyophilized blends with COA, HPLC, and MS language. That paperwork describes a seller's testing package; it does not establish the component ratio, sterility, or equivalence that define the studied drug.
Clinic and personal-use talk borrows the 2.4 mg/2.4 mg trial target, but the reviewed material does not establish one reliable real-world amount, frequency, or cycle for self-assembled combinations.
Use context
Routes, doses, and cycle patterns
The clearest schedule details come from trials and registries: once-weekly subcutaneous treatment, usually around a target 2.4 mg/2.4 mg CagriSema dose in longer obesity and diabetes studies. For research-use blends, the available sources mainly show marketing and product claims, not a dependable real-world schedule.
Human studies and product labels
Phase 2 type 2 diabetes combination trial
- Purpose
- Glycemic control and weight effects in type 2 diabetes
- Context
- Randomized phase 2 trial
- Route
- Subcutaneous
- Amount
- Cagrilintide 2.4 mg plus semaglutide 2.4 mg
- Frequency
- Once weekly
- Duration
- 32 weeks
The trial compared the combination with cagrilintide and semaglutide arms and reported larger weight loss than either component alone, with HbA1c improvement versus cagrilintide.
REDEFINE 1 obesity trial
- Purpose
- Weight management in adults with overweight or obesity without diabetes
- Context
- Phase 3 randomized trial and registry
- Route
- Subcutaneous
- Amount
- Target CagriSema 2.4 mg/2.4 mg
- Frequency
- Once weekly
- Duration
- 68 weeks
The trial reported 20.4% mean weight loss under treatment-policy analysis and 22.7% under ideal-adherence analysis, so the analysis type changes the headline number.
REDEFINE 2 obesity plus type 2 diabetes trial
- Purpose
- Weight management in adults with type 2 diabetes
- Context
- Phase 3 randomized trial and registry
- Route
- Subcutaneous
- Amount
- Target CagriSema 2.4 mg/2.4 mg
- Frequency
- Once weekly
- Duration
- 68 weeks
The trial reported 13.7% mean weight loss under treatment-policy analysis and 15.7% under ideal-adherence analysis in a diabetes population.
REIMAGINE 2 diabetes comparator update
- Purpose
- HbA1c and body-weight effects in adults with type 2 diabetes
- Context
- PubMed-indexed phase 3 comparator study plus sponsor update
- Route
- Subcutaneous
- Amount
- CagriSema 2.4 mg/2.4 mg and lower-dose arms
- Frequency
- Once weekly
- Duration
- 68 weeks
REIMAGINE 2 now has a PubMed-indexed study record, and Novo reported greater HbA1c reduction and greater weight loss with CagriSema than semaglutide across tested doses. This is current diabetes-program evidence, but it is not an FDA label.
REIMAGINE 1 diabetes study
- Purpose
- HbA1c and body-weight effects in adults with type 2 diabetes not on drug therapy
- Context
- Sponsor phase 3 program update
- Route
- Subcutaneous
- Amount
- CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg
- Frequency
- Once weekly
- Duration
- 40 weeks
Novo reported that REIMAGINE 1 tested once-weekly CagriSema against dose-matched placebo in adults with type 2 diabetes inadequately controlled on diet and exercise.
REIMAGINE 3 basal-insulin add-on study
- Purpose
- HbA1c and body-weight effects in adults using basal insulin
- Context
- Sponsor phase 3 program update
- Route
- Subcutaneous
- Amount
- CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg
- Frequency
- Once weekly
- Duration
- 40 weeks
Novo reported that REIMAGINE 3 tested once-weekly CagriSema against dose-matched placebo as add-on therapy in adults with type 2 diabetes on basal insulin with or without metformin.
REDEFINE 4 head-to-head obesity trial
- Purpose
- Direct comparison with tirzepatide
- Context
- Company-filed phase 3 result
- Route
- Subcutaneous
- Amount
- CagriSema 2.4 mg/2.4 mg versus tirzepatide 15 mg
- Frequency
- Once weekly
- Duration
- 84 weeks
Novo reported 23% weight loss with CagriSema, but the primary noninferiority endpoint versus tirzepatide was not met.
Real-world discussion
Combination-imitation discussion
- Purpose
- Weight loss
- Context
- Forums, vendor bundles, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- No fixed community protocol exists because CagriSema itself is an investigational combination. Community discussion typically imitates the trial concept by combining separately sourced cagrilintide and semaglutide at trial-referenced weekly amounts.
- Frequency
- Once weekly in trial-referenced discussion
- Duration
- Multi-month runs in community logs
CagriSema is not an approved product, and the fixed-ratio combination used in trials is not what community sources assemble from separate vials. Component identity and ratios are unverified. Not verified as a regimen; context only.
What varies
- Context: randomized trials support efficacy in defined populations; FDA pages describe legal status and safety concerns; vendor listings mostly show product claims and quality-document gaps.
- Dose number: 2.4 mg/2.4 mg in a trial is a studied regimen description. It does not tell you whether a seller's vial contains that ratio.
- Population: obesity without diabetes, obesity with type 2 diabetes, and insulin-treated diabetes change baseline risk, weight response, glucose goals, and safety interpretation.
- Analysis method: treatment-policy and ideal-adherence estimates can produce different headline weight-loss numbers.
- Product quality: identity, sterility, endotoxin, concentration, storage, reconstitution, and shipping matter more than a purity percentage alone.
Human data
Human evidence
For an investigational program, the human evidence is unusually deep: two phase 3 obesity trials, a phase 2 diabetes trial, a PubMed-indexed phase 3 diabetes comparator in REIMAGINE 2, sponsor reporting across the wider REIMAGINE program, and a company-filed head-to-head against tirzepatide. REDEFINE 4 supplies direct comparator context without showing superiority. The open questions are approval labeling, long-term outcomes, cardiovascular benefit, and validation of any non-trial blend. On that last point the record is empty.
Evidence maturity
CagriSema has unusually strong phase 3 human data for an investigational program, but approval is still pending and no gray-market blend matches the trial product.
Phase 1b coadministration work paired the amylin analogue cagrilintide with the GLP-1 agonist semaglutide.
The randomized combination trial reported larger weight loss than either component alone in type 2 diabetes.
REDEFINE 1 and REDEFINE 2 reported 13.7% to 22.7% mean weight loss depending on population and analysis, with the REIMAGINE studies adding diabetes comparators.
REDEFINE 4 reported 23% weight loss but missed its primary noninferiority endpoint against tirzepatide 15 mg.
Novo filed a U.S. NDA in December 2025 with an FDA decision expected in late 2026, and no online blend is verified against the studied fixed-ratio product.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Phase 2 type 2 diabetes trial | Adults with type 2 diabetes and overweight or obesity | Randomized phase 2 trial | Investigational product | Weekly cagrilintide 2.4 mg plus semaglutide 2.4 mg produced larger weight loss than either component alone and larger HbA1c reduction than cagrilintide alone. | Phase 2 diabetes data are smaller than the phase 3 program and do not supply approved prescribing, long-term outcomes, or online product equivalence. | Moderate |
| REDEFINE 1 | Adults with overweight or obesity without diabetes | Phase 3 randomized trial | Investigational product | Mean weight loss at 68 weeks was 20.4% under treatment-policy analysis and 22.7% under ideal-adherence analysis. | The result applies to the studied product and population. It does not support a 25% average-loss claim or confirm research-use blends. | Strong |
| REDEFINE 2 | Adults with overweight or obesity and type 2 diabetes | Phase 3 randomized trial | Investigational product | Mean weight loss at 68 weeks was 13.7% under treatment-policy analysis and 15.7% under ideal-adherence analysis. | The diabetes population had a smaller average weight-loss response than REDEFINE 1, so obesity-without-diabetes figures do not carry into diabetes claims. | Strong |
| REIMAGINE 2 | Adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor | PubMed-indexed phase 3 comparator study plus sponsor update | Investigational product | REIMAGINE 2 is now PubMed-indexed, and Novo reported superior HbA1c reduction and weight loss versus semaglutide across tested doses, including CagriSema 2.4 mg/2.4 mg. | A PubMed-indexed diabetes-comparator study adds stronger human evidence, but final regulator-reviewed labeling, long-term outcomes, and real-world use are still not available. | Moderate |
| REIMAGINE 1 and REIMAGINE 3 | Adults with type 2 diabetes in diet-and-exercise or basal-insulin backgrounds | Sponsor-reported phase 3 program update | Investigational product | Novo reported that both studies met glycemic and body-weight endpoints in their studied diabetes populations, using once-weekly 1 mg/1 mg and 2.4 mg/2.4 mg CagriSema dose levels. | Sponsor updates are useful early findings, but full peer-reviewed publications and final regulator-reviewed labeling would carry more weight. | Moderate |
| REDEFINE 4 | Adults with obesity and at least one comorbidity | Open-label phase 3 head-to-head trial | Investigational product | Novo reported 23% mean weight loss with CagriSema after 84 weeks, but the trial did not demonstrate noninferiority to tirzepatide 15 mg. | This is company-filed head-to-head context, not support for a claim that CagriSema beats tirzepatide. | Moderate |
| FDA and online-product materials | Trial-to-product comparison context | FDA safety and compounding communications | Online-product and compounding-enforcement context | FDA states compounded drugs are not FDA-approved, warns about compounded semaglutide dosing errors, and says cagrilintide cannot be used in compounding under federal law. | FDA pages do not evaluate every seller, but they show why product access, identity, concentration, and legality still have to be shown; the CagriSema name does not prove them. | Strong |
Cautions
Safety and unknowns
- Gastrointestinal adverse events are the dominant trial tolerability theme. Available trial reports show high rates of nausea, constipation, vomiting, and other GI events in CagriSema arms, with some discontinuations.
- Trial and company updates do not include a final CagriSema approval label, so contraindications, rare-event rates, monitoring instructions, and special-population wording remain unsettled for the combination.
- The semaglutide component brings label-level background concerns from approved semaglutide products, including pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, diabetic retinopathy risk in some patients with type 2 diabetes, and pregnancy uncertainty, but those are component-context facts rather than a CagriSema label.
- Cardiovascular-event reduction has not been shown for CagriSema. Weight loss and HbA1c changes are not substitutes for a completed cardiovascular outcomes result.
- Online and compounded-product risks include wrong concentration, confusing dose units, contamination, unstable shipping, incomplete sterility controls, and a blend ratio that may not match what the label or listing implies.
Product quality
A vial label is only a starting point
A COA or HPLC purity claim can document a seller's test report. Sterile injectable manufacturing, endotoxin control, correct component ratio, concentration accuracy, chain of custody, and equivalence to Novo's clinical product are separate checks.
FDA's compounded semaglutide alert describes real dosing-error problems from vial concentration differences, syringe confusion, and unit conversions. A combination product can make those problems harder, not easier.
FDA states cagrilintide cannot be used in compounding under federal law, which makes routine compounding claims especially risky for any product marketed as CagriSema.
Identity
The label "CagriSema" is only a name unless both components are present, correctly characterized, and in the intended ratio.
Sterility and endotoxin
Purity and mass-spectrometry claims leave sterile manufacturing and handling unanswered.
Concentration and dose math
FDA has warned that compounded injectable semaglutide errors can come from concentration differences and unit conversions; a two-component blend adds another layer of uncertainty.
Stability and shipping
Lyophilized peptide blends can be affected by storage, reconstitution, heat exposure, and shipping conditions that sit outside a generic COA.
Mechanism
How it is proposed to work
CagriSema combines two appetite and metabolic signaling systems. Semaglutide activates GLP-1 receptors, while cagrilintide was designed as a longer-acting amylin analogue. The idea is to pair GLP-1 effects with amylin-related satiety signaling rather than simply increasing semaglutide alone.
Cagrilintide was developed to improve on native amylin's practical limitations and provide longer-acting amylin-receptor activity for metabolic research.
Early coadministration work and later CagriSema trials test whether the amylin and GLP-1 mechanisms produce greater weight and glycemic effects together than either component alone.
Mechanism helps explain why the combination is plausible, but the named randomized trials are what support the weight-loss and HbA1c claims.
CagriSema combines two complementary satiety mechanisms: cagrilintide's amylin-receptor activity in the area postrema plus semaglutide's GLP-1 receptor activity.
FAQ
Common questions
Is CagriSema FDA-approved?
CagriSema remains investigational. Novo Nordisk says the weight-management application was submitted to FDA, but no FDA approval label is available.
Is CagriSema just semaglutide?
No. CagriSema combines cagrilintide and semaglutide. That means component evidence and combination evidence need to stay separate.
Do CagriSema trial results confirm compounded combinations?
No. FDA states compounded drugs are not FDA-approved, separately warns about compounded semaglutide concerns, and states that cagrilintide cannot be used in compounding under federal law.
Details
Technical details
Sources
References
- 1.
PubMed. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity 2025.
doi:10.1056/NEJMoa2502081 PMID:40544433 Accessed 2026-06-09.
Peer-reviewed REDEFINE 1 phase 3 trial source for CagriSema in adults with overweight or obesity without type 2 diabetes.
- 2.
PubMed. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes 2025.
doi:10.1056/NEJMoa2502082 PMID:40544432 Accessed 2026-06-09.
Peer-reviewed REDEFINE 2 phase 3 trial source for CagriSema in adults with overweight or obesity and type 2 diabetes.
- 3.
PubMed. Efficacy and safety of co-administered once-weekly cagrilintide with once-weekly semaglutide in type 2 diabetes 2023.
doi:10.1016/S0140-6736(23)01163-7 PMID:37364590 Accessed 2026-06-09.
Peer-reviewed phase 2 type 2 diabetes source for the cagrilintide plus semaglutide combination evidence.
- 4.
ClinicalTrials.gov. REDEFINE 1 ClinicalTrials.gov record 2026.
NCT05567796 Accessed 2026-06-09.
Registry record for the REDEFINE 1 phase 3 obesity / overweight CagriSema trial.
- 5.
ClinicalTrials.gov. REDEFINE 2 ClinicalTrials.gov record 2026.
NCT05394519 Accessed 2026-06-09.
Registry record for the completed REDEFINE 2 phase 3 CagriSema trial in overweight or obesity with type 2 diabetes.
- 6.
Accessed 2026-06-09.
Sponsor update used only for current development-program and regulatory-submission context; not a substitute for peer-reviewed publications or regulator-reviewed labeling.
- 7.
PubMed. Development of Cagrilintide, a Long-Acting Amylin Analogue 2021.
doi:10.1021/acs.jmedchem.1c00565 PMID:34288673 Accessed 2026-06-09.
Medicinal-chemistry source for the stable, lipidated long-acting amylin-analogue design and clinical-development rationale.
- 8.
doi:10.1016/S0140-6736(21)00845-X PMID:33894838 Accessed 2026-06-09.
Randomized phase 1b coadministration study; useful for separating cagrilintide-alone evidence from CagriSema combination evidence.
- 9.
FDA. Compounding and the FDA: Questions and Answers 2026.
Accessed 2026-06-08.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.
- 10.
FDA. Prime Sciences warning letter 2026.
Accessed 2026-06-09.
FDA warning letter naming Cagrilintide products offered online and describing unapproved new-drug and injectable-product safety concerns.
- 11.
Accessed 2026-06-08.
FDA distinguishes approved semaglutide products from compounded semaglutide products and describes dosing-error concerns.
- 12.
FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss 2026.
Accessed 2026-06-09.
FDA page states that cagrilintide cannot be used in compounding under federal law and has not been found safe and effective for any condition.
- 13.
PubMed. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2) 2026.
PMID:42251859 Accessed 2026-06-22.
PubMed-indexed REIMAGINE 2 phase 3 source used to separate peer-reviewed diabetes-comparator evidence from sponsor status updates.
- 14.
Accessed 2026-06-17.
Novo Nordisk announcement that a U.S. NDA was submitted for CagriSema in weight management; used for regulatory status context, not approval.
- 15.
SEC. Novo Nordisk Form 6-K dated February 23, 2026 2026.
Accessed 2026-06-17.
Company-filed REDEFINE 4 context: CagriSema 2.4/2.4 mg versus tirzepatide 15 mg over 84 weeks did not meet the primary noninferiority endpoint.
- 16.
Accessed 2026-06-17.
Sponsor REIMAGINE 1-3 program update; used for current diabetes-program context until peer-reviewed and regulator-reviewed sources are attached.